Clinical trials: OHT - Ocular Hypertension
Primary Open Angle Glaucoma
The Effects of an Antioxidant Formulation on Ocular Blood Flow
The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.
- Trial name
- NCT01930487
- Testing
- dietary supplement with antioxidants
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- ScienceBased Health
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers.
- Trial name
- NCT00716742
- Testing
- bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
- Where
- United States
- Volunteers
- 1,099 people
- Sponsor
- Allergan
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
- Trial name
- NCT00751062
- Testing
- timolol, PhXA41
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Glaucoma
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
- Trial name
- NCT03825380
- Testing
- Bimatoprost, Lumigan®
- Where
- Estonia
- Volunteers
- 485 people
- Sponsor
- Laboratoires Thea
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Open-angle Glaucoma, Ocular Hypertension
Adherence Assessment With Travalert Dosing Aid
The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.
- Trial name
- NCT00508469
- Testing
- Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav), Travoprost 0.004% eye drops, Timolol 0.05% eye drops
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
ELAZOP Switching Study in Korea
The purpose of this study is to assess the safety and efficacy of switching to ELAZOP from prior pharmacotherapy in patients with open-angled glaucoma.
- Trial name
- NCT01055366
- Testing
- Elazop (Azarga)
- Where
- 10 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Ocular Hypertension
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
This study will evaluate the safety and efficacy of PF 03187207.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
- Trial name
- NCT00441883
- Testing
- PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle
- Where
- 19 sites in United States
- Volunteers
- 176 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Hypertension, Open Angle Glaucoma
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
- Trial name
- NCT02874846
- Testing
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C
The purpose of this study was to assess the safety and efficacy of AL-59412C injected intravitreally relative to Vehicle.
- Trial name
- NCT01312454
- Testing
- AL-59412C injectable solution, Travoprost injectable solution, AL-59412C Vehicle
- Volunteers
- 4 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial
The objective of this study is to evaluate the effectiveness (Intra-Ocular Pressure lowering) and safety of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese subjects with Primary Open Angle Glaucoma or Ocular…
- Trial name
- NCT05043831
- Testing
- DSLT
- Sponsor
- BelkinVision
Open-Angle Glaucoma
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma
The purpose of this study is to determine whether Anecortave Acetate is effective for lowering intraocular pressure caused by open-angle glaucoma.
- Trial name
- NCT00705770
- Testing
- Anecortave Acetate
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma
STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
A study of the Streamline Surgical System versus competitor
- Trial name
- VENICE (NCT05280366)
- Testing
- Streamline Surgical System, iStent Inject W
- Where
- 20 sites in United States, Costa Rica and 1 more
- Volunteers
- 150 people
- Sponsor
- New World Medical, Inc.
Glaucoma, Ocular Hypertension
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
- Trial name
- NCT00767494
- Testing
- Travoprost/Brinzolamide fixed combination, Azopt, Travatan
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Alcon Research